Identification of a CEACAM5 targeted nanobody for positron emission tomography imaging and near-infrared fluorescence imaging of colorectal cancer
- 14 March 2023
- journal article
- research article
- Published by Springer Nature in European Journal of Nuclear Medicine and Molecular Imaging
- Vol. 50 (8) , 2305-2318
Abstract
Purpose Here, we aim to identify a CEACAM5-targeted nanobody and demonstrate its application in positron emission tomography (PET) imaging and near-infrared (NIR) fluorescence imaging in colorectal cancer (CRC). Methods Immunohistochemistry was applied to verify CEACAM5 expression in CRC and metastatic lymph nodes (mLNs). CEACAM5-targeted nanobodies were obtained by immunization of human CEACAM5 protein in a dromedary, followed by several rounds of phage screenings. Immunofluorescence staining and flow cytometry was carried out to determine the binding affinity of the nanobodies. The nanobodies were radiolabeled by coupling 18F-SFB for PET imaging of CRC subcutaneous xenografts and lymph node metastasis (LNM). IRDye800CW (IR800) were conjugated to form NIR probes for NIR imaging in CRC subcutaneous models. Results CEACAM5 was overexpressed in either human CRC tissues or mLNs. A CEACAM5 targeted nanobody, Nb41 was successfully generated, with excellent in vitro binding properties. Incorporation of albumin binding domain (ABD) did not affect the affinity of Nb41. In vivo imaging showed that both 18F-FB-Nb41 and 18F-FB-Nb41-ABD showed obvious accumulation in the tumor. Due to the longer retention in the blood, 18F-FB-Nb41-ABD enrichment in tumors was significantly delayed but higher compared to 18F-FB-Nb41. Both 18F-FB-Nb41 and 18F-FB-Nb41-ABD showed prominent LNM enrichment. Similarly, the IR800-conjugated nanobodies Nb41-IR800 and Nb41-ABD-IR800 exhibited superior imaging effects in subcutaneous models, while Nb41-ABD-IR800 exhibited higher fluorescence intensity in the tumor accompanied with a remarkedly delay compared to Nb41-IR800. Conclusion Collectively, we presented the identification and in vivo validation of a CEACAM5-targeted nanobody and a fused nanobody with an ABD, which enabled to the non-invasive visualization of malignancy of CRC using PET imaging and NIR imaging in subcutaneous models as well as LNM models.Keywords
Funding Information
- The Department of Science and Technology of Guangdong Province to the Guangdong Provincial Key Laboratory of Biomedical Imaging (2018B030322006)
This publication has 33 references indexed in Scilit:
- Development of Double-Stranded siRNA Labeling Method Using Positron Emitter and Its In Vivo Trafficking Analyzed by Positron Emission TomographyBioconjugate Chemistry, 2010
- The use of fluorescent dyes and probes in surgical oncologyEuropean Journal of Surgical Oncology, 2010
- Imaging Tumors with an Albumin-Binding Fab, a Novel Tumor-Targeting AgentCancer Research, 2007
- Ablynx Makes Nanobodies from Llama BodiesChemistry & Biology, 2006
- Does Positron Emission Tomography Change Management in Primary Rectal Cancer? A Prospective AssessmentDiseases of the Colon & Rectum, 2004
- The carcinoembryonic antigen (CEA) family: structures, suggested functions and expression in normal and malignant tissuesSeminars in Cancer Biology, 1999
- Oncological applications of positron emission tomography with fluorine-18 fluorodeoxyglucoseEuropean Journal of Nuclear Medicine and Molecular Imaging, 1996
- Carcinoembryonic antigen family: Characterization of cDNAs coding for NCA and CEA and suggestion of nonrandom sequence variation in their conserved loop-domainsGenomics, 1988
- [76] Use of monoclonal antibodies as radiopharmaceuticals for the localization of human carcinoma xenografts in athymic mice1986
- SPECIFIC CARCINOEMBRYONIC ANTIGENS OF THE HUMAN DIGESTIVE SYSTEMJournal of Experimental Medicine, 1965